Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:MRVI NASDAQ:QURE NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$35.46+4.0%$39.55$16.50▼$48.45$3.30BN/A7,049 shs2,065 shsMRVIMaravai LifeSciences$3.41-2.0%$2.85$1.66▼$8.29$870.78M0.331.64 million shs985,960 shsQUREuniQure$61.01+2.8%$35.42$5.35▼$65.14$3.35B0.563.55 million shs1.01 million shsXENEXenon Pharmaceuticals$40.76-1.1%$38.91$26.74▼$46.00$3.14B1.14811,494 shs858,981 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+0.06%-6.26%-6.19%+3,545,999,900.00%MRVIMaravai LifeSciences0.00%+3.33%+26.77%+26.77%-53.73%QUREuniQure0.00%+5.19%+15.88%+303.77%+848.10%XENEXenon Pharmaceuticals0.00%-2.09%+11.61%+34.52%-2.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$35.46+4.0%$39.55$16.50▼$48.45$3.30BN/A7,049 shs2,065 shsMRVIMaravai LifeSciences$3.41-2.0%$2.85$1.66▼$8.29$870.78M0.331.64 million shs985,960 shsQUREuniQure$61.01+2.8%$35.42$5.35▼$65.14$3.35B0.563.55 million shs1.01 million shsXENEXenon Pharmaceuticals$40.76-1.1%$38.91$26.74▼$46.00$3.14B1.14811,494 shs858,981 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+0.06%-6.26%-6.19%+3,545,999,900.00%MRVIMaravai LifeSciences0.00%+3.33%+26.77%+26.77%-53.73%QUREuniQure0.00%+5.19%+15.88%+303.77%+848.10%XENEXenon Pharmaceuticals0.00%-2.09%+11.61%+34.52%-2.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AMRVIMaravai LifeSciences 2.08Hold$5.2253.04% UpsideQUREuniQure 2.83Moderate Buy$71.7517.60% UpsideXENEXenon Pharmaceuticals 2.92Moderate Buy$53.6731.67% UpsideCurrent Analyst Ratings BreakdownLatest MRVI, AAPG, XENE, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025QUREuniQureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025MRVIMaravai LifeSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025XENEXenon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025QUREuniQureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025XENEXenon PharmaceuticalsBloom BurtonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/7/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.0010/6/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$70.00 ➝ $110.0010/6/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$70.00 ➝ $110.0010/2/2025QUREuniQureWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$65.00 ➝ $80.009/27/2025MRVIMaravai LifeSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$390.60M8.46N/AN/A$0.48 per share73.88MRVIMaravai LifeSciences$259.18M3.36$0.62 per share5.52$2.28 per share1.50QUREuniQure$27.12M123.44N/AN/A($0.14) per share-435.79XENEXenon Pharmaceuticals$9.43M333.30N/AN/A$9.90 per share4.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AMRVIMaravai LifeSciences-$144.85M-$1.36N/AN/AN/A-90.03%-17.60%-9.30%11/6/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)Latest MRVI, AAPG, XENE, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025XENEXenon Pharmaceuticals-$1.16N/AN/AN/AN/AN/A11/6/2025Q3 2025MRVIMaravai LifeSciences-$0.06N/AN/AN/A$49.02 millionN/A11/4/2025Q3 2025QUREuniQure-$0.87N/AN/AN/A$4.46 millionN/A8/11/2025Q2 2025XENEXenon Pharmaceuticals-$1.03-$1.07-$0.04-$1.07N/AN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53MRVIMaravai LifeSciences0.685.164.49QUREuniQure1.539.989.98XENEXenon PharmaceuticalsN/A15.1415.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AMRVIMaravai LifeSciences50.25%QUREuniQure78.83%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AMRVIMaravai LifeSciences2.11%QUREuniQure4.79%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.17 millionN/AN/AMRVIMaravai LifeSciences610255.36 million249.97 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableXENEXenon Pharmaceuticals21077.11 million73.97 millionOptionableMRVI, AAPG, XENE, and QURE HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. $XENE Shares Acquired by Mutual of America Capital Management LLCOctober 25 at 4:20 AM | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Xenon (XENE)October 23 at 7:31 AM | theglobeandmail.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 18, 2025 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 18, 2025 | marketbeat.comXenon Pharmaceuticals appoints Tucker Kelly as Chief Financial OfficerOctober 16, 2025 | msn.comXenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization EffortsOctober 16, 2025 | tipranks.comXenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of AzetukalnerOctober 16, 2025 | quiverquant.comQXenon Announces Appointment of Tucker Kelly as Chief Financial OfficerOctober 16, 2025 | globenewswire.comXenon (XENE) Receives a Buy from JefferiesOctober 16, 2025 | theglobeandmail.comXenon Pharmaceuticals (NASDAQ:XENE) Earns "Sell (D-)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comInvestors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)October 16, 2025 | marketbeat.comAberdeen Group plc Boosts Position in Xenon Pharmaceuticals Inc. $XENEOctober 15, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Given "Sell (D-)" Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comXenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price MomentumOctober 12, 2025 | finance.yahoo.comResearch Analysts Issue Forecasts for XENE FY2025 EarningsOctober 10, 2025 | marketbeat.comBrokers Offer Predictions for XENE FY2026 EarningsOctober 8, 2025 | marketbeat.comBloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy"October 8, 2025 | marketbeat.comChardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy RecommendationOctober 7, 2025 | msn.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | globenewswire.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William BlairOctober 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025QURE: Why Analysts See Up to 63% Upside After 250% Single-Day PopBy Leo Miller | October 3, 2025Breakout Momentum Plays You Need to Know AboutBy Nathan Reiff | October 23, 2025MRVI, AAPG, XENE, and QURE Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$35.46 +1.38 (+4.05%) As of 10/24/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Maravai LifeSciences NASDAQ:MRVI$3.41 -0.07 (-2.01%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.41 0.00 (0.00%) As of 10/24/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.uniQure NASDAQ:QURE$61.01 +1.68 (+2.83%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$61.31 +0.30 (+0.49%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Xenon Pharmaceuticals NASDAQ:XENE$40.76 -0.44 (-1.07%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$40.76 0.00 (0.00%) As of 10/24/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
